- Home
- AXSM vs SF Comparison
AXSM vs SF Comparison
Compare AXSM & SF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AXSM | SF |
|---|---|---|
| Founded | 2012 | 1890 |
| Country | United States | United States |
| Employees | N/A | 9000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 11.2B |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | AXSM | SF |
|---|---|---|
| Price | $236.31 | $78.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 7 |
| Target Price | ★ $211.12 | $90.33 |
| AVG Volume (30 Days) | 878.2K | ★ 1.3M |
| Earning Date | 05-04-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 1.76% |
| EPS Growth | ★ 38.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $57.24 | $14.58 |
| Revenue Next Year | $55.88 | $8.03 |
| P/E Ratio | ★ N/A | $20.53 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $96.09 | $67.81 |
| 52 Week High | $260.19 | $134.74 |
Technical Indicators
Market Signals| Indicator | AXSM | SF |
|---|---|---|
| Relative Strength Index (RSI) | 47.92 | 66.65 |
| Support Level | $236.44 | $75.78 |
| Resistance Level | $256.40 | $79.12 |
| Average True Range (ATR) | 9.67 | 2.07 |
| MACD | -2.09 | 0.68 |
| Stochastic Oscillator | 42.72 | 98.30 |
Price Performance
Historical ComparisonAbout AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
About SF Stifel Financial Corporation
Stifel Financial is a diversified financial-services provider that generates revenue from wealth management, investment banking, and lending. The firm was founded in 1890 as a St. Louis-based full-service brokerage but has been transformed under CEO Ronald Kruszewski through a slew of acquisitions into a globally competitive wealth manager, investment bank, and retail and institutional brokerage. The firm generated $5.5 billion in revenue in 2025, with roughly two-thirds derived from wealth management and one-third derived from trading and investment banking.